BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 26590814)

  • 1. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.
    Wolfe AR; Debeb BG; Lacerda L; Larson R; Bambhroliya A; Huang X; Bertucci F; Finetti P; Birnbaum D; Van Laere S; Diagaradjan P; Ruffell B; Trenton NJ; Chu K; Hittelman W; Diehl M; Levental I; Ueno NT; Woodward WA
    Breast Cancer Res Treat; 2015 Dec; 154(3):495-508. PubMed ID: 26590814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.
    Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K
    J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin promotes cardiac microvascular endothelial cells proliferation, migration and survival by phosphorylation of p70 S6K and FoxO3a.
    Pan Q; Xie X; Guo Y; Wang H
    Cell Biol Int; 2014 May; 38(5):599-609. PubMed ID: 24375611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCN5/WISP-2 promotes growth arrest of triple-negative breast cancer cells through accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation.
    Haque I; Banerjee S; De A; Maity G; Sarkar S; Majumdar M; Jha SS; McGragor D; Banerjee SK
    Oncogene; 2015 Jun; 34(24):3152-63. PubMed ID: 25132260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin suppresses osteoblastic expression of Cyr61 and progression of apical periodontitis through enhancement of the transcription factor Forkhead/winged helix box protein O3a.
    Lin LD; Lin SK; Chao YL; Kok SH; Hong CY; Hou KL; Lai EH; Yang H; Lee MS; Wang JS
    J Endod; 2013 May; 39(5):619-25. PubMed ID: 23611379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin inhibits cysteine-rich protein 61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of sirtuin-1/FoxO3a signaling.
    Kok SH; Lin LD; Hou KL; Hong CY; Chang CC; Hsiao M; Wang JH; Lai EH; Lin SK
    Arthritis Rheum; 2013 Mar; 65(3):639-49. PubMed ID: 23239110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
    Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
    Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
    Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
    Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo.
    Ananda Sadagopan SK; Mohebali N; Looi CY; Hasanpourghadi M; Pandurangan AK; Arya A; Karimian H; Mustafa MR
    J Exp Clin Cancer Res; 2015 Dec; 34():147. PubMed ID: 26643256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.
    Chen J; Gomes AR; Monteiro LJ; Wong SY; Wu LH; Ng TT; Karadedou CT; Millour J; Ip YC; Cheung YN; Sunters A; Chan KY; Lam EW; Khoo US
    PLoS One; 2010 Aug; 5(8):e12293. PubMed ID: 20808831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
    Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
    Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
    Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
    Espinoza I; Liu H; Busby R; Lupu R
    Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.
    Gagliardi M; Pitner MK; Park J; Xie X; Saso H; Larson RA; Sammons RM; Chen H; Wei C; Masuda H; Chauhan G; Kondo K; Tripathy D; Ueno NT; Dalby KN; Debeb BG; Bartholomeusz C
    Sci Rep; 2020 May; 10(1):8537. PubMed ID: 32444778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.